A Phase 4 interventional study of Dulaglutide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-16.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 54th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 4, and was the 34th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 225th largest by enrollment of the 232 interventional ones that give a count, is one of 12 that started in 2017, is one of 33 in phase 4, and was the 133rd registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the glucodynamic effects of dulaglutide in Japanese participants with type 2 diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
Drug: Dulaglutide · Drug: Placebo
Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
Drug: Dulaglutide · Drug: Placebo
Administered SC
Also known as: LY2189265
Administered SC
Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h])
Least square (LS) means of glucose AUC 0-4h change from baseline was calculated using mixed-effects linear model. The model will include treatment, sequence, period, week, and treatment-by-week as fixed effects, baseline as a covariate, and participant as random effect.
Time frame: Baseline, 4 Weeks
Change From Baseline in Fasting Blood Glucose
Change from baseline in fasting blood glucose obtained at pre-meal.
Time frame: Baseline, 4 Weeks
Change From Baseline in Postprandial Blood Glucose
Change from baseline in postprandial blood glucose at 120 minutes at week 4.
Time frame: Baseline, 4 Weeks
Change From Baseline in Insulin Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])
LS mean of the insulin change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.
Time frame: Baseline, 4 Weeks
Change From Baseline in C-Peptide Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])
LS mean of C-peptide change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.
Time frame: Baseline, 4 Weeks
Change From Baseline in Glucagon Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])
LS mean of glucagon change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.
Time frame: Baseline, 4 Weeks
Change From Baseline in Triglyceride Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])
LS mean of triglyceride change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.
Time frame: Baseline, 4 Weeks
Number of Participants Who Develop Hypoglycemic Events
Number of participants who develop hypoglycemic events.
Time frame: Baseline through 4 weeks
| Milestone | Dulaglutide Then Placebo | Placebo Then Dulaglutide |
|---|---|---|
| Started | 6 | 6 |
| Received one dose of study drug | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Dulaglutide Then Placebo | Placebo Then Dulaglutide |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
Least square (LS) means of glucose AUC 0-4h change from baseline was calculated using mixed-effects linear model. The model will include treatment, sequence, period, week, and treatment-by-week as fixed effects, baseline as a covariate, and participant as random effect.
| milligram*hour per deciliter (mg*h/dL) | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h]) | -238.46 (-293.87 to -183.05) | 15.56 (-71.27 to 102.39) |
Change from baseline in fasting blood glucose obtained at pre-meal.
| milligrams per deciliter (mg/dL) | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Fasting Blood Glucose | -39.8 ± 33.3 | -8.2 ± 21.5 |
Change from baseline in postprandial blood glucose at 120 minutes at week 4.
| mg/dL | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Postprandial Blood Glucose | -67.0 ± 32.1 | 13.9 ± 28.7 |
LS mean of the insulin change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.
| insulin units*h/mL (µU*h/mL) | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Insulin Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h]) | 25.20 (7.29 to 43.10) | -2.27 (-11.39 to 6.85) |
LS mean of C-peptide change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.
| nanogram*h/milliliter (ng*h/mL) | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in C-Peptide Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h]) | 3.58 (0.44 to 6.72) | -0.14 (-1.24 to 0.96) |
LS mean of glucagon change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.
| picomole*h/Liter (pmol*h/L) | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Glucagon Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h]) | -16.39 (-25.69 to -7.09) | -7.02 (-12.81 to -1.24) |
LS mean of triglyceride change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.
| mg*h/dL | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Triglyceride Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h]) | 31.02 (-54.70 to 116.74) | 46.41 (-76.55 to 169.38) |
Number of participants who develop hypoglycemic events.
| Participants | Dulaglutide | Placebo |
|---|---|---|
| Number of Participants Who Develop Hypoglycemic Events | 0 | 0 |
Collected over Baseline up to 14 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dulaglutide | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Placebo | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Event | Dulaglutide | Placebo |
|---|---|---|
| InfluenzaInfections and infestations | 2/12 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 1/12 |
| NauseaGastrointestinal disorders | 1/12 | 0/12 |
| Periodontal diseaseGastrointestinal disorders | 0/12 | 1/12 |
| PericoronitisInfections and infestations | 0/12 | 1/12 |
| PeriodontitisInfections and infestations | 0/12 | 1/12 |
| PharyngitisInfections and infestations | 1/12 | 0/12 |
| Viral upper respiratory tract infectionInfections and infestations | 0/12 | 1/12 |
| Decreased appetiteMetabolism and nutrition disorders | 1/12 | 0/12 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 58.9 ± 7.1 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 2 |
| Male | 10 |
| Race/Ethnicity, Customized(Participants) | Overall |
|---|---|
| Asian | 12 |
| Region of Enrollment(Participants) | Overall |
|---|---|
| Japan | 12 |
| Duration of Diabetes(years) | Overall |
|---|---|
| Mean | 8.5 ± 7.7 |
| Screening HbA1c(percentage of HbA1c) | Overall |
|---|---|
| Mean | 7.9 ± 1.2 |
| Fasting Blood Glucose(milligram per deciliter (mg/dL)) | Overall |
|---|---|
| Mean | 164.67 ± 22.18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2017 to primary completion in Feb 2018, 4 months.
Results were first posted in Apr 2019, 1 year 2 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 4 months is below that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide